Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCM vs Western Medicine for Long COVID
NCT06095258Phase 2Not yet recruiting
- Sponsor
- The Chinese University of Hong Kong
- Start
- Dec 2023
- Primary completion
- Nov 2025
- Modality
- HMF (Herbal Medicine Formulation)
01
Overview
A Phase 2 trial of bazhengsan in post-acute sequelae of SARS-CoV-2 infection (PASC), sponsored by The Chinese University of Hong Kong. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
bazhengsan
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06095258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06095258.